| Name | Title | Contact Details |
|---|---|---|
Mike Robinson |
VP of Engineering | Profile |
ACEA Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Uromedica is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.